Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRP?), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRP? as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRP? activity.

Abstract: Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

Abstract: Provided herein are antibodies that bind signal regulatory protein SIRP? and methods of making and using such antibodies. In some embodiments, the antibodies comprise an Fc, and are useful for preferential depletion of certain SIRP? expressing cells. In some embodiments, the antibodies provided herein are useful for treating a disease or condition associated with the dysregulation of cells (e.g. overactivation or aberrant proliferation of T-cells).

Abstract: Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

Abstract: Quadrantanopial occlusive lenses and method of use includes the steps of performing a vision zone assessment test to identify a field area of a patient's field of view having a selected characteristic, based on the identified field area, providing an appliance having a non-transparent optical characteristic associated with the field area, the patient wearing the appliance, and while the patient is wearing the appliance, the patient performing a selected activity associated with the neurological performance. The neurological performance may be associated with the quality of performance of the selected activity. The selected activity may be a physical activity. The step of performing a vision zone assessment test may include moving a visual target about the patient's field of view. The step of performing a vision zone assessment test may include observing the patient's eye movements in response to a moving visual stimulus.

Abstract: Embodiments of the present disclosure generally relate to methods for analyzing outcomes of illnesses, such as COVID-19, on living organisms. More particularly, embodiments of the present disclosure relate to methods for identifying risk of illness based on genetic markers and other available data, predicting results of mass exposure to an Illness based on a populations genomes and other available data, and providing indicators and methods of visualization for probability of illness in any living organism.

Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRP?), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRP? as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRP? activity.

Abstract: Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

Abstract: A method includes obtaining a rule that is associated with a segment of a map, determining a state for use in evaluation of the rule, evaluating the rule using the state, identifying an action to be performed based on a result of evaluating the rule using the state, and utilizing the action to be performed as an input to an automated control system of a vehicle.

Abstract: Provided herein are antibodies that bind signal regulatory protein gamma (SIRPy), as well as SIRP? and/or SIRP?1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRPy as well as SIRP? and/or SIRP?1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP?, SIRP?1 and/or SIRPy activity.

Abstract: A kit of eyewear that comprises a plurality of eyewear elements, each having a frame and a lens associated with each eye. Each of the eyewear elements have an occluded portion of at least one lens; at least some of the eyewear elements having different occlusion areas on the left and right lenses; and the eyewear elements having different occlusions patterns from each other.

Abstract: Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting, e.g. by depleting the circulating levels of TFPI, by disrupting a Protein S-TFPI complex, and/or by preventing the formation of a Protein S-TFPI complex.

Abstract: Provided herein are antibodies that bind signal regulatory protein SIRPa, SIRPß1, or a combination of SIRPa and SIRP?1, and methods of using such antibodies. In some embodiments, the antibodies are human monoclonal antibodies that bind human SIRPa and/or SIRP?1. In some embodiments, the antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of myeloid cells, or a disease or condition associated with SIRPa and/or SIRP?1 activity.

Abstract: Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

Abstract: Embodiments of the present disclosure generally relate to methods for analyzing the effectiveness of preventative measures on the spread of illnesses, such as COVID-19, on living organisms. More particularly, embodiments of the present disclosure relate to methods for identifying the effectiveness of preventative measures, processes, equipment and other available data, and providing indicators and methods of visualization the effectiveness of preventative measures on the spread of an illness.

Abstract: Embodiments of the present disclosure generally relate to methods for analyzing survivability of illnesses, such as COVID-19. More particularly, embodiments of the present disclosure relate to methods for identifying correlations and influencing factors between genetic markers, lifestyle, and other available data that lead to predictions of the effectiveness of medical treatments, predicting results of mass exposure to an illness based on a population's genomes and other available data, and providing indicators and methods of visualization for survivability of a viral infection or cancer in any living organism.

Abstract: Embodiments of the present disclosure generally relate to methods for analyzing outcomes of illnesses, such as COVID-19, on living organisms. More particularly, embodiments of the present disclosure relate to methods for identifying risk of illness based on genetic markers and other available data, predicting results of mass exposure to an Illness based on a populations genomes and other available data, and providing indicators and methods of visualization for probability of illness in any living organism.

Abstract: Embodiments of the present disclosure generally relate to methods for analyzing survivability of illnesses, such as COVID-19. More particularly, embodiments of the present disclosure relate to methods for identifying correlations and influencing factors between genetic markers, lifestyle, and other available data that lead to predictions of the effectiveness of medical treatments, predicting results of mass exposure to an illness based on a population's genomes and other available data, and providing indicators and methods of visualization for survivability of a viral infection or cancer in any living organism.

Abstract: Embodiments of the present disclosure generally relate to methods for analyzing outcomes of illnesses, such as COVID-19, on living organisms. More particularly, embodiments of the present disclosure relate to methods for identifying risk of illness based on genetic markers and other available data, predicting results of mass exposure to an Illness based on a populations genomes and other available data, and providing indicators and methods of visualization for probability of illness in any living organism.

Abstract: A method is provided for void-free Ru metal filling of features in a substrate. The method includes providing a substrate containing features, depositing a Ru metal layer in the features, removing the Ru metal layer from a field area around an opening of the features, and depositing additional Ru metal in the features, where the additional Ru metal is deposited in the features at a higher rate than on the field area. According to one embodiment, the additional Ru metal is deposited until the features are fully filled with Ru metal.